BSRBR: Demyelinating Disease Following Anti-TNFα Therapy Analysis of patients receiving TNFi therapy in the BSRBR shows that the risk of demyelination is rare but is marginally increased by taking TNFi therapy. https://t.co/oHJXOa96Kn https://t.co/m2GpeEQxnP